Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

Genital Warts Clinical Trial

Official title:

A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01796821
• Other study ID #: GESRTGWA
• Status: Completed
• Phase: Phase 2
• Start date: August 2014
• Est. completion date: October 2018

Study information

• Verified date: February 2020
• Source: G&E Herbal Biotechnology Co., LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy of SR-T100 gel by observing total clearance rate of treated baseline EGW(s) on the treated area.

Description:

A double-blind, randomized,vehicle-controlled, parallel-group, and dose-ranging study to evaluate the efficacy and safety of SR-T100 gel in patients with EGW(s). The primary efficacy endpoint will be defined as the proportion of patients whose baseline EGW(s) on the treated area achieve total clearance. The efficacy of SR-T100 gel in prevention of new EGW(s) occurrence will be evaluated. Distinct to existing medications for EGWs, SR-T100 gel possesses characteristics of high safety and low LSR causality. SR-T100 gel will be administered on EGW lesion(s) for clearance and on the surrounding clinical normal skin for prevention of new EGW(s) occurrence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 138
• Est. completion date: October 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Male or female; aged = 20 years old.

2. Patients who accept to enter the study by signing written informed consent.

3. Each patient has 1 to 10 clinically diagnosed EGW(s). If patient has only 1 genital wart, the diameter of the genital wart must be no less than 5 mm.

4. Female patients have lesion(s) on labia majora, labia minora, clitoris and/or groin.

5. Male patients have lesion(s) on glans, shaft and/or foreskin.

6. Each patient has at least 1 histologically proved EGW.

7. Patients agree to apply the study medication on "clinical diagnosed lesion(s)" with occlusive dressing(s) once daily for at least 20 hours per day and "clinical normal skin on the treated area" thrice daily without occlusive dressing.

8. Patients allow diagrammed mapping and photography on genital warts. And patients agree to be used of these data as part of the study data package.

9. Patients in good general health condition (performance status = 2 Eastern Cooperative Oncology Group (ECOG)).

10. Female patients with child-bearing potential must take reliable contraception method(s) during the participation of the study.

11. Patients must agree to use effective boundary barrier for birth control and re-infection of EGW

Exclusion Criteria:

1. Patients with peri-anal warts.

2. Male patients with warts on scrotum or perineum.

3. Patients with other genital infections.

4. Patients with internal genital warts (such as urethral, intra-vaginal, cervical, rectal, or intra-anal genital warts).

5. Patients with active systemic infections.

6. Patients with other genital diseases that may confound evaluation and treatment for genital warts.

7. Patients with immuno-compromised medical condition.

8. Patients have received investigational drug prior to 30 days of randomization visit.

9. Patients with cancer or cancer history within 5 years of the randomization visit.

10. Patients have on-going human papilloma virus (HPV) infection other than genital area.

11. Patients with human immunodeficiency virus (HIV), venereal disease research laboratory (VDRL), or treponema pallidum particle agglutination assay (TPHA) positive result.

12. Female patients have high-grade pathology in Papanicolaou smear tests based on Bethesda system.

13. Female patients are pregnant or lactating.

14. Patients have history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.

15. Patients with prohibited pre-medication or procedures shown below:

1. Physical modalities, such as laser ablation, electrocautery or cryotherapy, for genital warts treatment on treated area within 4 weeks prior to randomization visit.

2. Topical administered medication for genital warts treatment, such as polyphenon E, podophyllotoxin, imiquimod, or 5-fluorouracil (5-FU), within 12 weeks prior to randomization.

3. Medications of cytotoxic, immunomodulator (inhaled and topical steroid not on ano-genital areas are not prohibited), systematic antiviral agent in 4 weeks prior to randomization visit.

Related Conditions & MeSH terms

• Condyloma Acuminata
• Condylomata Acuminata
• Genital Warts
• Venereal Warts
• Warts

Intervention

Drug:
• Vehicle gel
Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application <1,500 mg gel per day.
• SR-T100 gel with 1.0 % SM
Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application <1,500 mg gel per day.
• SR-T100 gel with 2.3% SM
Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing. Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing. Total application <1,500 mg gel per day.

Locations

Country	Name	City	State
Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	Kaohsiung Municipal Ta-Tung Hospital	Kaohsiung
Taiwan	National Cheng Kung University Hospital	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
G&E Herbal Biotechnology Co., LTD

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total clearance rate of baseline lesion(s)		16 weeks
Secondary	Total clearance rate of all lesion(s)		16 weeks
Secondary	Period duration of achieving total clearance of baseline lesion(s) and new lesion(s)		16 weeks
Secondary	Partial clearance rate		16 weeks
Secondary	New lesion(s) occurrence rate		16 weeks
Secondary	Recurrence rate in the 12-week follow-up time		28 weeks
Secondary	Recurrence time period		28 weeks
Secondary	Safety: evaluate the changes occurring from baseline to EOT visit	including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.	28 weeks